(SMG) Scotts Miracle-Gro - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8101861065
Stock: Lawn Care, Garden Products, Hydroponics, Pest Control
Total Rating 36
Risk 73
Buy Signal -0.06
| Risk 5d forecast | |
|---|---|
| Volatility | 40.9% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.27 |
| Alpha | -13.49 |
| Character TTM | |
|---|---|
| Beta | 0.934 |
| Beta Downside | 1.721 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.42% |
| CAGR/Max DD | -0.01 |
EPS (Earnings per Share)
Revenue
Description: SMG Scotts Miracle-Gro March 05, 2026
The Scotts Miracle-Gro Company (SMG) manufactures and sells lawn, garden, and hydroponic products globally. The company operates in the consumer staples sector, specifically within fertilizers and agricultural chemicals.
SMGs product portfolio includes lawn care items like fertilizers and weed control, gardening products such as potting mixes and plant foods, and hydroponic growing systems. This business model relies on both direct consumer sales and distribution through various retail channels, including home centers, garden centers, and e-commerce platforms, demonstrating a broad market reach typical of established consumer brands.
The company markets products under numerous brands, including Scotts, Miracle-Gro, Ortho, and Roundup. These brands cover a wide range of gardening and home pest control solutions. Further research on platforms like ValueRay can provide detailed financial metrics and competitive analysis.
Headlines to watch out for
- Consumer spending on lawn and garden products impacts sales
- Hydroponics market growth drives Hawthorne segment revenue
- Input costs for fertilizers and chemicals affect margins
- Regulatory changes for cannabis cultivation create market volatility
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 89.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -3.65 > 1.0 |
| NWC/Revenue: 9.69% < 20% (prev 16.90%; Δ -7.21% < -1%) |
| CFO/TA 0.15 > 3% & CFO 446.2m > Net Income 89.8m |
| Net Debt (2.52b) to EBITDA (448.6m): 5.62 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.9m) vs 12m ago 1.05% < -2% |
| Gross Margin: 30.98% > 18% (prev 0.25%; Δ 3.07k% > 0.5%) |
| Asset Turnover: 108.0% > 50% (prev 112.3%; Δ -4.25% > 0%) |
| Interest Coverage Ratio: 3.08 > 6 (EBITDA TTM 448.6m / Interest Expense TTM 122.3m) |
Altman Z'' 1.77
| A: 0.11 (Total Current Assets 1.26b - Total Current Liabilities 932.4m) / Total Assets 3.03b |
| B: 0.04 (Retained Earnings 131.2m / Total Assets 3.03b) |
| C: 0.12 (EBIT TTM 376.7m / Avg Total Assets 3.10b) |
| D: 0.11 (Book Value of Equity 371.9m / Total Liabilities 3.53b) |
| Altman-Z'' Score: 1.77 = BBB |
Beneish M -3.43
| DSRI: 0.96 (Receivables 193.8m/213.6m, Revenue 3.35b/3.56b) |
| GMI: 0.80 (GM 30.98% / 24.81%) |
| AQI: 0.95 (AQ_t 0.38 / AQ_t-1 0.40) |
| SGI: 0.94 (Revenue 3.35b / 3.56b) |
| TATA: -0.12 (NI 89.8m - CFO 446.2m) / TA 3.03b) |
| Beneish M-Score: -3.43 (Cap -4..+1) = AA |
What is the price of SMG shares?
As of March 17, 2026, the stock is trading at USD 62.16 with a total of 722,272 shares traded.
Over the past week, the price has changed by -3.36%, over one month by -10.21%, over three months by +7.05% and over the past year by +5.98%.
Over the past week, the price has changed by -3.36%, over one month by -10.21%, over three months by +7.05% and over the past year by +5.98%.
Is SMG a buy, sell or hold?
Scotts Miracle-Gro has received a consensus analysts rating of 4.36.
Therefore, it is recommended to buy SMG.
- StrongBuy: 7
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SMG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75.5 | 21.5% |
| Analysts Target Price | 75.5 | 21.5% |
SMG Fundamental Data Overview March 16, 2026
P/E Trailing = 21.8495
P/E Forward = 14.2248
P/S = 1.0403
P/B = 21.9459
P/EG = 0.708
Revenue TTM = 3.35b USD
EBIT TTM = 376.7m USD
EBITDA TTM = 448.6m USD
Long Term Debt = 2.25b USD (from longTermDebt, last quarter)
Short Term Debt = 278.3m USD (from shortTermDebt, last quarter)
Debt = 2.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.52b USD (from netDebt column, last quarter)
Enterprise Value = 6.06b USD (3.54b + Debt 2.53b - CCE 8.30m)
Interest Coverage Ratio = 3.08 (Ebit TTM 376.7m / Interest Expense TTM 122.3m)
EV/FCF = 16.92x (Enterprise Value 6.06b / FCF TTM 358.1m)
FCF Yield = 5.91% (FCF TTM 358.1m / Enterprise Value 6.06b)
FCF Margin = 10.69% (FCF TTM 358.1m / Revenue TTM 3.35b)
Net Margin = 2.68% (Net Income TTM 89.8m / Revenue TTM 3.35b)
Gross Margin = 30.98% ((Revenue TTM 3.35b - Cost of Revenue TTM 2.31b) / Revenue TTM)
Gross Margin QoQ = 25.03% (prev 6.07%)
Tobins Q-Ratio = 2.00 (Enterprise Value 6.06b / Total Assets 3.03b)
Interest Expense / Debt = 1.08% (Interest Expense 27.2m / Debt 2.53b)
Taxrate = 34.51% (76.5m / 221.7m)
NOPAT = 246.7m (EBIT 376.7m * (1 - 34.51%))
Current Ratio = 1.35 (Total Current Assets 1.26b / Total Current Liabilities 932.4m)
Debt / Equity = -5.05 (negative equity) (Debt 2.53b / totalStockholderEquity, last quarter -500.6m)
Debt / EBITDA = 5.62 (Net Debt 2.52b / EBITDA 448.6m)
Debt / FCF = 7.04 (Net Debt 2.52b / FCF TTM 358.1m)
Total Stockholder Equity = -329.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 89.8m / Total Assets 3.03b)
RoE = -27.23% (negative equity) (Net Income TTM 89.8m / Total Stockholder Equity -329.8m)
RoCE = 19.62% (EBIT 376.7m / Capital Employed (Equity -329.8m + L.T.Debt 2.25b))
RoIC = 12.26% (NOPAT 246.7m / Invested Capital 2.01b)
WACC = 5.75% (E(3.54b)/V(6.07b) * Re(9.36%) + D(2.53b)/V(6.07b) * Rd(1.08%) * (1-Tc(0.35)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.05%
[DCF] Terminal Value 80.82% ; FCFF base≈410.9m ; Y1≈269.7m ; Y5≈123.1m
[DCF] Fair Price = 24.16 (EV 3.92b - Net Debt 2.52b = Equity 1.40b / Shares 58.0m; r=5.90% [WACC]; 5y FCF grow -39.99% → 2.90% )
EPS Correlation: -17.91 | EPS CAGR: -29.02% | SUE: 0.93 | # QB: 1
Revenue Correlation: -32.77 | Revenue CAGR: -33.95% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.85 | Chg7d=-0.006 | Chg30d=-0.006 | Revisions Net=+0 | Analysts=8
EPS current Year (2026-09-30): EPS=4.29 | Chg7d=+0.005 | Chg30d=+0.006 | Revisions Net=+2 | Growth EPS=+14.6% | Growth Revenue=-3.0%
EPS next Year (2027-09-30): EPS=4.88 | Chg7d=+0.002 | Chg30d=+0.017 | Revisions Net=+2 | Growth EPS=+13.7% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.8% (Discount Rate 9.4% - Earnings Yield 4.6%)
[Growth] Growth Spread = -2.8% (Analyst 2.0% - Implied 4.8%)
P/E Forward = 14.2248
P/S = 1.0403
P/B = 21.9459
P/EG = 0.708
Revenue TTM = 3.35b USD
EBIT TTM = 376.7m USD
EBITDA TTM = 448.6m USD
Long Term Debt = 2.25b USD (from longTermDebt, last quarter)
Short Term Debt = 278.3m USD (from shortTermDebt, last quarter)
Debt = 2.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.52b USD (from netDebt column, last quarter)
Enterprise Value = 6.06b USD (3.54b + Debt 2.53b - CCE 8.30m)
Interest Coverage Ratio = 3.08 (Ebit TTM 376.7m / Interest Expense TTM 122.3m)
EV/FCF = 16.92x (Enterprise Value 6.06b / FCF TTM 358.1m)
FCF Yield = 5.91% (FCF TTM 358.1m / Enterprise Value 6.06b)
FCF Margin = 10.69% (FCF TTM 358.1m / Revenue TTM 3.35b)
Net Margin = 2.68% (Net Income TTM 89.8m / Revenue TTM 3.35b)
Gross Margin = 30.98% ((Revenue TTM 3.35b - Cost of Revenue TTM 2.31b) / Revenue TTM)
Gross Margin QoQ = 25.03% (prev 6.07%)
Tobins Q-Ratio = 2.00 (Enterprise Value 6.06b / Total Assets 3.03b)
Interest Expense / Debt = 1.08% (Interest Expense 27.2m / Debt 2.53b)
Taxrate = 34.51% (76.5m / 221.7m)
NOPAT = 246.7m (EBIT 376.7m * (1 - 34.51%))
Current Ratio = 1.35 (Total Current Assets 1.26b / Total Current Liabilities 932.4m)
Debt / Equity = -5.05 (negative equity) (Debt 2.53b / totalStockholderEquity, last quarter -500.6m)
Debt / EBITDA = 5.62 (Net Debt 2.52b / EBITDA 448.6m)
Debt / FCF = 7.04 (Net Debt 2.52b / FCF TTM 358.1m)
Total Stockholder Equity = -329.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 89.8m / Total Assets 3.03b)
RoE = -27.23% (negative equity) (Net Income TTM 89.8m / Total Stockholder Equity -329.8m)
RoCE = 19.62% (EBIT 376.7m / Capital Employed (Equity -329.8m + L.T.Debt 2.25b))
RoIC = 12.26% (NOPAT 246.7m / Invested Capital 2.01b)
WACC = 5.75% (E(3.54b)/V(6.07b) * Re(9.36%) + D(2.53b)/V(6.07b) * Rd(1.08%) * (1-Tc(0.35)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.05%
[DCF] Terminal Value 80.82% ; FCFF base≈410.9m ; Y1≈269.7m ; Y5≈123.1m
[DCF] Fair Price = 24.16 (EV 3.92b - Net Debt 2.52b = Equity 1.40b / Shares 58.0m; r=5.90% [WACC]; 5y FCF grow -39.99% → 2.90% )
EPS Correlation: -17.91 | EPS CAGR: -29.02% | SUE: 0.93 | # QB: 1
Revenue Correlation: -32.77 | Revenue CAGR: -33.95% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.85 | Chg7d=-0.006 | Chg30d=-0.006 | Revisions Net=+0 | Analysts=8
EPS current Year (2026-09-30): EPS=4.29 | Chg7d=+0.005 | Chg30d=+0.006 | Revisions Net=+2 | Growth EPS=+14.6% | Growth Revenue=-3.0%
EPS next Year (2027-09-30): EPS=4.88 | Chg7d=+0.002 | Chg30d=+0.017 | Revisions Net=+2 | Growth EPS=+13.7% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.8% (Discount Rate 9.4% - Earnings Yield 4.6%)
[Growth] Growth Spread = -2.8% (Analyst 2.0% - Implied 4.8%)